CVP (with rituximab, R-CVP)
Checked 2026-09-09
Follicular and other indolent B-cell lymphomas needing treatment, when an anthracycline is not wanted
Also called CVP, R-CVP.
One cycle
every 21 days × 8 · about 24 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Rituximab Monoclonal antibody (anti-CD20, chimeric) | 375 mg/m² (R-CVP) | IV | D1 | |
Cyclophosphamide Alkylating agent (oxazaphosphorine prodrug) | 750 mg/m² | IV | D1 | |
Vincristine Vinca alkaloid (microtubule inhibitor) | 1.4 mg/m² (maximum 2 mg) | IV | D1 | |
Prednisone Glucocorticoid | 40 mg/m² once daily | Oral | D1-5 |
Cycles
8
21-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- Adding rituximab to CVP improved response and time to treatment failure; bendamustine-rituximab has since displaced R-CVP for many patients.
Used in
Source
Marcus, Blood 2005: R-CVP versus CVP in follicular lymphoma
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
R-CHOP
Diffuse large B-cell lymphoma, first line (6 cycles; 3-4 with radiotherapy for limited stage)
every 21 days × 6
Bendamustine + rituximab (BR)
Indolent lymphoma and mantle cell lymphoma first line; fit CLL without del(17p) where targeted agents are unavailable
every 28 days × 6
Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T
Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma
every 6 days